RAG1 and neoplasm: To determine whether the residual Treg population seen in PC61-treated mice (Figures 1A and 1B) might be sufficient to affect DC function in tumor-bearing mice, we examined tumor-specific T cell proliferation in RAG1−/− mice, which lack all T cells including Treg.